Italia markets closed

Dow Jones
40.033,40
+29,81(+0,07%)
Nasdaq
16.786,23
+100,26(+0,60%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0864
-0,0008(-0,08%)
Bitcoin EUR
62.019,93
+498,31(+0,81%)
CMC Crypto 200
1.372,09
+17,67(+1,30%)

NVCR Jun 2024 20.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,4000

-0,4500

(-52,94%)

In data: 11:30AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in